BioTuesdays
Matinas BioPharma Holdings
Feature

Matinas BioPharma moves focus to anti-infectives

By Len Zehr After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. “Our...

July 28, 2015
Feature

In conversation with Heather Morehouse Ettinger

By Len Zehr As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and...

July 14, 2015
Feature

Provectus taking novel path to treat cancer

By Len Zehr Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...

May 19, 2015
Feature

T2 Biosystems to double sales force this year

By Len Zehr T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx...

May 12, 2015
Feature

In conversation with Dr. Shai Yarkoni

By Len Zehr As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start...

April 21, 2015
Feature

In conversation with Greg Trudel

By Len Zehr As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with...

April 14, 2015
Feature

Relmada championing four pain drug candidates

By Len Zehr Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. “It is very unusual for a...

April 7, 2015
Feature

In conversation with Dr. Isaac Ciechanover

By Len Zehr As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through...

March 31, 2015
Feature

Actinium gearing up for pivotal trial in second half

By Len Zehr Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute...

March 24, 2015
Feature

Ocular Therapeutix eyeing sustained drug delivery

By Len Zehr Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to...

March 17, 2015
Feature

Synergy Disc Replacement sets global sales plan

By Len Zehr After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution...

March 3, 2015
Feature

In conversation with Steve Damon

By Len Zehr As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible...

February 24, 2015
Feature

Neovasc launching Reducer in Europe for RA

Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. Alexei...

February 17, 2015